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to	 identify	 novel	 susceptibility	 loci	 for	DKD.15,16	However,	 these	 studies’	 findings	 remain	 inconsistent,	 demonstrating	 that	 it	 is	 difficult	 to	 identify	 the	 genetic	mechanism	 involved	 in	 the	 complex	 disease	 of	DKD
(reviewed	by	Regele	et	al17),	suggesting	that	a	new	approach	could	be	useful.
















developed	 diabetic	 kidney	 hypertrophy,	while	 the	 reciprocal	 FVB.Dkh1/2b	 congenic	 strain	was	 protected.	 The	 chr6	 locus	 contained	 the	 candidate	 gene;	 Ark1b3,	 coding	 aldose	 reductase;	 the	 FVB	 allele	 has	 a	missense








































Gene	name Chromosome log2-fold	change P	value Accession	number Gene	function
MGST1 6 4.1525 0.0013 NM_019946.4 Microsomal	glutathione	S-transferase
INMT 6 3.1824 0.0005 NM_009349.1 N-methylation	of	endogenous	and
xenobiotic	compounds
SSPN 6 2.8882 0.0019 NM_010656.2 A	link	between	the	F-actin	cytoskeleton
and	the	extracellular	matrix
COL1A2 6 2.2643 0.0130 NM_007743.2 Forms	pro-alpha2	chain	of	type	I
collagen
FGFR1OP2 6 1.9604 0.0028 NM_026218.2 Protein	homodimerization	activity
H2AFJ 6 1.4490 0.0382 NM_177688.2 Involved	in	the	nucleosome	structure	of
the	chromosomal	fiber
AKR1B3 6 1.2663 0.0105 NM_009658.2 aldo/keto	reductase	superfamily
ABCC9 6 1.2420 0.0132 NM_021041.2 Sulfonylurea	receptor	2
PARP12 6 1.1947 0.0282 NM_172893.2 NAD+	ADP-ribosyltransferase	activity
ART4 6 1.0005 0.0240 NM_026639.2 Post-translational	modification
AKR1B8 6 0.9823 0.0268 NM_008012.1 aldo/keto	reductase	superfamily
TACSTD2 6 0.7366 0.0557 NM_020047.3 Encodes	a	carcinoma-associated	antigen
KRAS 6 −1.2616 0.0118 NM_021284.4 Proto-oncogene
Figure	6	Interactive	QTL	analyses	of	mouse	chromosomes	6	and	12.	Additive	interactions	are	shown	above	the	diagonal.	Epistatic	interactions	are	represented	below	the	diagonal.	Chromosomes	are	shown	on	the	horizontal	and	vertical	axes.	Significant	thresholds	are
indicated	in	red	on	the	heat	map	(scale	at	the	right).	Additive	and	epistatic	logarithm	of	odds	(LOD)	scores	were	significant	if	they	exceeded	the	values	of	7	and	3,	respectively.
ANXA4 6 −1.3881 0.0159 NM_013471.1 Membrane-related	events	along	the
exocytotic	and	endocytotic	pathways
SLC13A4 6 −2.0417 0.0033 NM_172892.1 Transporter	activity	and	sodium:sulfate
symporter	activity
BCAT1 6 −2.0759 0.0165 NM_007532.2 Catalyzes	the	reversible	transamination
MAP4K5 12 1.3232 0.0109 NM_024275.2 Encodes	a	member	of	the
serine/threonine	protein	kinase	family
1700047I17RIK1 12 1.2245 0.0276 NM_028527.1 Uncharacterized
MBOAT2 12 1.1832 0.0165 NM_001083341.1 1-Acylglycerol-3-phosphate	O-
acyltransferase	activity
TTC15 12 −1.1545 0.0248 NM_178811.3 Affiliated	with	noncoding	RNA
BC022687 12 −1.2319 0.0211 NM_145450.3 Clathrin	binding	box	of	aftiphilin
containing	1
GREB1 12 −1.3871 0.0094 NM_015764.1 Important	role	in	hormone-responsive
tissues	and	cancer
SERPINA3H 12 −1.4869 0.0056 NM_001034870.2 Uncharacterized





























































































Table	S1.	Oligonucleotide	primer	sequences	 for	Mit	and	WAD	markers	used	 to	genotype	 (FVB	×	B6)	F2	mice.	Markers	on	chromosomes	6	and	12	are	 represented,	 and	 the	primers	 that	 are	associated	with	 the	congenic
intervals	are	shown	in	red.	The	outermost	primers	determine	the	congenic	intervals.
Table	S2.	Differential	expression	of	genes	between	B6	and	FVB	diabetic	and	control	kidneys.	Genes	differentially	expressed	on	chromosome	6	between	diabetic	and	control	FVB	kidneys:	(i)	genes	differentially	expressed	on
chromosome	12	between	diabetic	and	control	FVB	kidneys;	(ii)	genes	are	listed	in	terms	of	the	log-fold	change,	along	with	the	P	value,	chromosome	number,	and	accession	number.
Supplementary	material	is	linked	to	the	online	version	of	the	paper	at	www.kidney-international.org.
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